Adriamycin, Doxorubicin supplier & exporter
Product Description
API name | Adriamycin, Doxorubicin |
CAS Number | 23214-92-8 |
Therapeutic Category | Anticancer, Antineoplastic |
Route of Administration | Injection, Powder, solution |
Regulatory Documents | TECH PACK, DMF |
Trader & Wholesaler of Adriamycin, Doxorubicin
Mechanism of Action:
Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Drug Indications:
Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.